Hypoglycemia: Difference between revisions
No edit summary
Line 22: Line 22:
##1mg SC or IM
##1mg SC or IM


===Hypoglycemia from Sulfonylureas<ref>Rowden AK, Fasano CJ. Emergency management of oral hypoglycemic drug toxicity. Emerg Med
{{Sulfonylurea Toxicity}}
Clin N Am 2007; 25:347-356</ref><ref>Howland MA. Antidotes in Depth: Octreotide. In: Flomenbaum NE, Goldfrank LR, Hoffman RS et al,
eds: Goldfrank’s Toxicologic Emergencies. New York NY, 2006;770-773</ref>===
#D50 should be given initially
#Start a D10 1/2NS drip  (5mL/hr)
#Octreotide<ref>Fasano CJ et al. Comparison of Octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia. Ann Emerg Med 2008; 51:400-406</ref>
#*Theoretical benefit to reduce risk of recurrent hypoglycemia
#*Hyperpolarization of the beta cell results in inhibition of Ca influx and prevents insulin release
#*50-100 mcg subcutaneous in adults with repeat dosing Q6hrs
#*2 mcg/kg subcutaneously should be used in children
#*Continuous infusion of 50-125 mcg/hr is an alternative in adults
#Do NOT use a glucagon drip
#*Glucagon also has an insulin-releasing effect and may subsequently cause hypoglycemia


===Hypoglycemia from Long Acting Insulin===
===Hypoglycemia from Long Acting Insulin===

Revision as of 18:27, 25 May 2014

Diagnosis

  1. Symptoms consistent with the diagnosis
  2. Symptoms associated with a low glucose level, usually <50
  3. Symptoms resolve with glucose administration

DDX

  1. Medication-induced
  2. Sepsis
  3. Toxin
  4. Insulinoma
  5. Hepatic failure
  6. Adrenal insufficiency

Treatment

ED or Prehospital

  1. D50
  2. Oral glucose intake
  3. Glucagon[1]
    1. Efficacy dependent on hepatic glycogen stores
    2. Onset of action slower than IV dextrose (7-10min)
    3. 1mg SC or IM

Hypoglycemia from Sulfonylureas[2][3]

Activated charcoal[4]

  • Administer activated charcoal, preferably within 1 hr of ingestion
  • Multiple doses may be beneficial, especially for glipizide

Glucose Treatment

  • Initial therapy regardless of known cause
Adults
  • 50mL D50W bolus
  • Start a D10 1/2NS drip (100mL/hr)
Children
  • 1mL/kg of D50W OR
  • 2mL/kg D25W OR 5-10mL/kg D10W
  • Neonate: 5-10 mL/kg D10W

Octreotide[5]

  • Theoretical benefit to reduce risk of recurrent hypoglycemia
  • Hyperpolarization of the beta cell results in inhibition of Ca influx and prevents insulin release
  • 50-100 mcg subcutaneous in adults with repeat dosing Q6hrs
  • 2 mcg/kg (max 150mcg) subcutaneously Q6hrs should be used in children
  • Continuous infusion of 50-125 mcg/hr is an alternative in adults
  • Administer octreotide for 24 hours, then after discontinuing, monitor for hypoglycemia for another 24 hours

Special Considerations

  • Glucagon 5mg IM may be used as temporizing measure, e.g. while obtaining IV access
    • Dependent on glycogen stores which may be depleted in prolonged hypoglycemia
    • Also short duration of action
    • Caution in using glucagon drip
      • Glucagon also has an insulin-releasing effect
      • May subsequently cause initial paradoxical hypoglycemia

Hypoglycemia from Long Acting Insulin

  • Similar treatment as for Sulfonylureas except no role for Octreotide
  • Treatment should include oral PO intake as well as maintenance glucose containing drip either D5 or D10

Disposition

Consider admission for obs for sulfonylurea-induced hypoglycemia or long acting insulins

See Also

Sources

  1. ↑ Carstens S, Sprehn M. Prehospital treatment of severe hypoglycaemia: a comparison of intramuscular glucagon and intravenous glucose. Prehosp Disaster Med. 1998 Apr-Dec;13(2-4):44-50
  2. ↑ Rowden AK, Fasano CJ. Emergency management of oral hypoglycemic drug toxicity. Emerg Med Clin N Am 2007; 25:347-356
  3. ↑ Howland MA. Antidotes in Depth: Octreotide. In: Flomenbaum NE, Goldfrank LR, Hoffman RS et al, eds: Goldfrank’s Toxicologic Emergencies. New York NY, 2006;770-773
  4. ↑ Tran D et al. Oral Hypoglycemic Agent Toxicity Treatment & Management. Jul 14, 2015. http://emedicine.medscape.com/article/1010629-treatment#showall.
  5. ↑ Fasano CJ et al. Comparison of Octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia. Ann Emerg Med 2008; 51:400-406
Retrieved from "https://www.wikem.org/w/index.php?title=Hypoglycemia&oldid=21142"